Pharmacoeconomic Impact of Adverse Events of Long-Term Opioid Treatment for the Management of Persistent Pain.
- Published in:
- Clinical Drug Investigation, 2011, v. 31, n. 2, p. 73, doi. 10.1007/BF03256935
- Publication type:
- Article
Works matching IS 11732563 AND DT 2011 AND VI 31 AND IP 2
Results: 7
1
2
Use of Recombinant Human Parathyroid Hormone(1-84) in Patients with Postmenopausal Osteoporosis.
- Published in:
- Clinical Drug Investigation, 2011, v. 31, n. 2, p. 87, doi. 10.1007/BF03256936
- Publication type:
- Article
3
Safety of Recombinant Human Thrombopoietin in Adults after Related Donor Haploidentical Haematopoietic Stem Cell Transplantation.
- Published in:
- Clinical Drug Investigation, 2011, v. 31, n. 2, p. 135, doi. 10.1007/BF03256939
- Publication type:
- Article
4
Safety Data and Beneficial Effects of the Combined Oral Contraceptive Ethinylestradiol 0.03 mg/Chlormadinone Acetate 2 mg (Belara®).
- Published in:
- Clinical Drug Investigation, 2011, v. 31, n. 2, p. 121, doi. 10.2165/11585900-000000000-00000
- Publication type:
- Article
5
Assessment of the Potential for Displacement Interactions with Sugammadex.
- Published in:
- Clinical Drug Investigation, 2011, v. 31, n. 2, p. 101, doi. 10.1007/BF03256937
- Publication type:
- Article
6
Conversion from Epoetin Alfa to Darbepoetin Alfa for Management of Anaemia in a Community Chronic Kidney Disease Centre.
- Published in:
- Clinical Drug Investigation, 2011, v. 31, n. 2, p. 113, doi. 10.1007/BF03256938
- Publication type:
- Article
7
Clinical Drug Investigation.
- Published in:
- Clinical Drug Investigation, 2011, v. 31, n. 2, p. 72
- Publication type:
- Article